Rhumbline Advisers Apellis Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $104 Billion
  • Q1 2025

A detailed history of Rhumbline Advisers transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 124,454 shares of APLS stock, worth $2.28 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
124,454
Previous 124,454 -0.0%
Holding current value
$2.28 Million
Previous $3.02 Million 9.9%
% of portfolio
0.0%
Previous 0.0%

Shares

30 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

Apr 08, 2025
SELL
$21.87 - $34.63 $24,188 - $38,300
-1,106 Reduced 0.88%
124,454 $3.02 Million
Q4 2024

May 29, 2025
BUY
$26.18 - $35.42 $28,955 - $39,174
1,106 Added 0.89%
125,560 $4.01 Million
Q4 2024

Jan 30, 2025
SELL
$26.18 - $35.42 $7,723 - $10,448
-295 Reduced 0.23%
125,560 $4.01 Million
Q3 2024

Nov 12, 2024
BUY
$28.84 - $41.15 $66,043 - $94,233
2,290 Added 1.85%
125,855 $3.63 Million
Q2 2024

Aug 01, 2024
BUY
$38.07 - $59.71 $100,657 - $157,873
2,644 Added 2.19%
123,565 $4.74 Million
Q1 2024

May 09, 2024
SELL
$55.39 - $72.47 $701,514 - $917,832
-12,665 Reduced 9.48%
120,921 $7.11 Million
Q4 2023

Feb 08, 2024
BUY
$37.14 - $64.82 $47,984 - $83,747
1,292 Added 0.98%
133,586 $8 Million
Q3 2023

Nov 09, 2023
SELL
$23.65 - $89.22 $13,693 - $51,658
-579 Reduced 0.44%
132,294 $5.03 Million
Q2 2023

Aug 08, 2023
BUY
$76.68 - $93.31 $146,612 - $178,408
1,912 Added 1.46%
132,873 $12.1 Million
Q1 2023

May 11, 2023
BUY
$46.59 - $66.96 $16,772 - $24,105
360 Added 0.28%
130,961 $8.64 Million
Q4 2022

Feb 14, 2023
BUY
$43.24 - $61.04 $320,494 - $452,428
7,412 Added 6.02%
130,601 $6.75 Million
Q3 2022

Nov 10, 2022
BUY
$44.76 - $69.66 $593,338 - $923,412
13,256 Added 12.06%
123,189 $8.41 Million
Q2 2022

Aug 11, 2022
BUY
$35.07 - $59.21 $1.13 Million - $1.9 Million
32,169 Added 41.37%
109,933 $4.97 Million
Q1 2022

May 12, 2022
BUY
$35.46 - $54.12 $135,989 - $207,550
3,835 Added 5.19%
77,764 $3.95 Million
Q4 2021

Feb 10, 2022
BUY
$30.74 - $49.16 $139,375 - $222,891
4,534 Added 6.53%
73,929 $3.5 Million
Q3 2021

Nov 12, 2021
BUY
$31.4 - $69.84 $79,316 - $176,415
2,526 Added 3.78%
69,395 $2.29 Million
Q2 2021

Aug 05, 2021
BUY
$40.9 - $64.9 $83,313 - $132,201
2,037 Added 3.14%
66,869 $4.23 Million
Q1 2021

May 06, 2021
SELL
$40.8 - $57.39 $394,903 - $555,477
-9,679 Reduced 12.99%
64,832 $2.78 Million
Q4 2020

Feb 10, 2021
BUY
$30.79 - $57.2 $9,606 - $17,846
312 Added 0.42%
74,511 $4.26 Million
Q3 2020

Nov 12, 2020
SELL
$25.89 - $33.65 $420,375 - $546,375
-16,237 Reduced 17.95%
74,199 $2.24 Million
Q2 2020

Aug 13, 2020
BUY
$24.8 - $38.49 $322,474 - $500,485
13,003 Added 16.79%
90,436 $2.95 Million
Q1 2020

May 06, 2020
BUY
$17.91 - $44.33 $218,233 - $540,161
12,185 Added 18.67%
77,433 $2.07 Million
Q4 2019

Feb 05, 2020
BUY
$22.1 - $30.8 $64,090 - $89,320
2,900 Added 4.65%
65,248 $2 Million
Q3 2019

Oct 23, 2019
BUY
$24.09 - $32.18 $7,178 - $9,589
298 Added 0.48%
62,348 $1.5 Million
Q2 2019

Aug 14, 2019
BUY
$18.0 - $25.34 $281,682 - $396,545
15,649 Added 33.73%
62,050 $1.57 Million
Q1 2019

May 01, 2019
SELL
$12.81 - $19.82 $8,185 - $12,664
-639 Reduced 1.36%
46,401 $905,000
Q4 2018

Jan 31, 2019
BUY
$11.47 - $18.71 $174,630 - $284,859
15,225 Added 47.85%
47,040 $620,000
Q3 2018

Nov 07, 2018
SELL
$16.57 - $21.03 $35,410 - $44,941
-2,137 Reduced 6.29%
31,815 $566,000
Q2 2018

Aug 06, 2018
BUY
$19.63 - $30.0 $483,781 - $739,350
24,645 Added 264.8%
33,952 $747,000
Q1 2018

May 02, 2018
BUY
$14.01 - $26.02 $130,391 - $242,168
9,307 New
9,307 $206,000

Others Institutions Holding APLS

# of Institutions
295
Shares Held
124M
Call Options Held
921K
Put Options Held
761K
View Full List

About Apellis Pharmaceuticals, Inc.

APLS Quotes by TradingView
  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $2.01B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email